Bing

One stock that might be an intriguing choice for investors right now is Impax Laboratories Inc. ( IPXL). This is because this security in the Pharmaceutical industry space is seeing solid earnings estimate revision activity, and is in great company from a ...
NASDAQ · 3/14/2014
This suggests that analysts have very recently bumped up their estimates for IPXL, giving the stock a Zacks Earnings ESP of 15.00% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP has proven to be very ...
ZACKS · 5/8/2015
As previously disclosed, on October 8, 2014, Impax Laboratories (Nasdaq: IPXL) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Tower Holdings, Inc. (“Tower”), Lineage Therapeutics Inc. (“Lineage”), Roundtable ...
StreetInsider · 12/29/2014
According to the complaint the plaintiff alleges on behalf of purchasers of Impax Laboratories Inc (NASDAQ: IPXL) common stock during the period between June 6, 2011 and March 4, 2013, that Impax Laboratories Inc and certain of its officers and directors ...
wallstreetscope.com · 3/17/2015
Impax Laboratories (NASDAQ:IPXL) traded up 1.51% during midday trading on Tuesday, hitting $45.17. The stock had a trading volume of 810,892 shares. The stock has a market cap of $3.14 billion and a price-to-earnings ratio of 426.13. Impax …
Mideast Times · 8/15/2015
SAN FRANCISCO, Oct. 28, 2014 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is actively investigating alleged misconduct by Impax Laboratories Inc.'s IPXL, -2.05% top executives, including claims that Impax's officers and directors breached their …
Market Watch · 10/28/2014
Small cap specialty generic pharmaceutical stock IGI Laboratories, Inc (NYSEMKT: IG), who’s peers may include mid cap Akorn, Inc (NASDAQ: AKRX) and small caps Impax Laboratories Inc (NASDAQ: IPXL) and Lannett Company, Inc (NYSE: LCI), has …
Smallcap Network · 7/15/2015
Impax Laboratories Inc (NASDAQ:IPXL)’s stock gained the most in this list as it posted ... Get your FREE REPORT today (retail value of $300) This is a FREE report from Insider Monkey. Credit Card is NOT required.
INSIDER MONKEY · 4/16/2015
The top of the channel is near $59, so a reasonable profit target is just below this, at $58.50 to $58.75 Impax Laboratories Inc. (IPXL) rallied strongly from below $24 in October to $52.10 in April. That was were the stock peaked and it has been moving in ...
Investopedia · 7/15/2015
UBS downgraded Impax Laboratories Inc (NASDAQ: IPXL) Thursday from Neutral to Sell and maintained a $36 price target. Analyst Marc Goodman noted that the stock had run up on expectations that the company may get acquired or do other deals.
Benzinga · 4/17/2015